<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Sonoma Pharmaceuticals Inc (SNOA)</title>
    <description>Latest news, press releases, and SEC filings for Sonoma Pharmaceuticals Inc (SNOA)</description>
    <link>https://caymanjournal.com/stock/SNOA</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Tue, 28 Apr 2026 01:21:01 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/SNOA/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>S-1/A — Sonoma Pharmaceuticals, Inc.</title>
      <description># 🧾 What This Document Is
This is an **amended registration statement (S-1/A)** for Sonoma Pharmaceuticals. Think of it as the final, updated blueprint for selling new stock to the public. Its main purpose is to detail a planned **public offering** of &quot;units,&quot; where each unit is a bundle containing</description>
      <link>https://caymanjournal.com/stock/SNOA/sec-filing/0001683168-26-003139</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/SNOA/sec-filing/0001683168-26-003139</guid>
      <pubDate>Thu, 23 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>